Immunostimulatory compositions, particles, and uses related thereto

Abstract

In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

1 . A non-naturally occurring particle comprising,
 a lipid membrane;   a B7-1 or B7-2 molecule anchored to the lipid membrane on the exterior of the particle;   and   an antigen molecule anchored to the lipid membrane on the exterior of the particle.   
     
     
         2 . The particle of  claim 1  further comprising an adjuvant molecule anchored to the lipid membrane on the exterior of the particle wherein the adjuvant molecule and antigen molecule are not the same molecule. 
     
     
         3 . The particle of  claim 2 , wherein the adjuvant molecule is selected from molecules comprising IL-2, IL-12, ICAM1 GM-CSF, flagellin, unmethylated, CpG oligonucleotide, lipopolysaccharides, lipid A, and heat stable antigen (HSA). 
     
     
         4 . The particle of  claim 1 , wherein the lipid membrane is a phospholipid monolayer or phospholipid bilayer. 
     
     
         5 . The particle of  claim 1 , wherein the particle is a cell, allogeneic or autologous cancer cell or its membrane fragments or vesicles, liposome, virosome, micelle, polymer, or virus like particle. 
     
     
         6 . The particle of  claim 1 , wherein the B7-1 molecule is anchored to the lipid membrane on the exterior of the particle through a conjugated glycosyl-phosphatidylinositol, phospholipid, glycolipid, triglyceride, saturated or unsaturated fatty acid, or other lipophilic molecule. 
     
     
         7 . The particle of  claim 1 , wherein the antigen molecule is anchored to the lipid membrane on the exterior of the particle through a conjugated glycosyl-phosphatidylinositol, phospholipid, glycolipid, triglyceride, saturated or unsaturated fatty acid, or other lipophilic molecule. 
     
     
         8 . The particle of  claim 1 , wherein the adjuvant molecule is anchored to the lipid membrane on the exterior of the particle through a conjugated glycosyl-phosphatidylinositol, phospholipid, glycolipid, triglyceride, saturated or unsaturated fatty acid, or other lipophilic molecule. 
     
     
         9 . The particle of  claim 1 , wherein antigen is a cancer marker molecule selected from HER-2, MUC-1, mucin antigens TF, Tn, STn, glycolipid globo H antigen, prostatic acid phosphatase (PAP), prostate-specific antigen, prostate-specific membrane antigen, early prostate cancer antigen-2 (EPCA-2), bcl-2, G-protein coupled estrogen receptor 1, CA15-3, CA19-9, CA 72-4, CA-125, carcinoembryonic antigen, CD20, CD31, CD34, PTPRC (CD45), CD99, CD117, melanoma-associated antigen (TA-90), peripheral myelin protein 22 (PMP22), epithelial membrane proteins (EMP-1, -2, and -3), HMB-45 antigen, MART-1 (Melan-A), S100A1, and S100B. 
     
     
         10 . The particle of  claim 1 , wherein the antigen is contained in the interior of the particle. 
     
     
         11 . The particle of  claim 1 , wherein the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         12 . The particle of  claim 1 , wherein the antigen is HER-2 and the adjuvant is flagellin or GM-CSF. 
     
     
         13 . The particle of  claim 1 , wherein the antigen is HER-2 and the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         14 . The particle of  claim 1 , wherein the antigen is HER-2, the adjuvant is flagellin or GM-CSF, the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         15 . The particle of  claim 1 , wherein the antigen is HER-2 and the adjuvant is IL-12. 
     
     
         16 . The particle of  claim 1 , wherein the antigen is HER-2, the adjuvant is IL-12, the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         17 . The particle of  claim 1 , wherein the antigen is PSA or PAP and the adjuvant is flagellin or GM-CSF. 
     
     
         18 . The particle of  claim 1 , wherein the antigen is PSA or PAP and the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         19 . The particle of  claim 1 , wherein the antigen is PSA or PAP, the adjuvant is flagellin, the B7-1 molecule is a B7-1 and heat stable antigen (HSA) hybrid chimera. 
     
     
         20 . The particle of  claim 1 , wherein the antigen is PSA or PAP and the adjuvant is IL-12. 
     
     
         21 - 50 . (canceled)